Antimicrobial agents for complicated skin and skin-structure infections: Justification of noninferiority margins in the absence of placebo-controlled trials

Clinical Infectious Diseases

Volumn 49, Issue 3, 2009, Pages 383-391

  Spellberg, Brad ^a,b   Talbot, George H ^e   Boucher, Helen W ^f   Bradley, John S ^c,d   Gilbert, David ^g   Michael Scheld, W ^h   Edwards Jr , John ^a,b   Bartlett, John G ⁱ  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Talbot Advisors   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PENICILLIN G; PLACEBO; SULFONAMIDE;

CELLULITIS; CLINICAL TRIAL; DRUG EFFICACY; ERYSIPELAS; FOOD AND DRUG ADMINISTRATION; HUMAN; MORTALITY; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SKIN STRUCTURE; SYSTEMATIC REVIEW;

ANTI-INFECTIVE AGENTS; BACTERIA; DRUG APPROVAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SKIN DISEASES, BACTERIAL; TREATMENT OUTCOME; UNITED STATES;

EID: 67651119706     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/600296     Document Type: Review

References (80)

1. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic- resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 155-64.
2. Shlaes DM, Moellering RC Jr. The United States Food and Drug Administration and the end of antibiotics. Clin Infect Dis 2002; 34:420-2.
3. Gilbert DN, Edwards JE Jr. Is there hope for the prevention of future antimicrobial shortages? Clin Infect Dis 2002; 35:215-6; author reply 216-7.
4. Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol 2007; 28:1290-8.
5. Ellis Simonsen SM, van Orman ER, Hatch BE, et al. Cellulitis incidence in a defined population. Epidemiol Infect 2006; 134:293-9.
6. McNamara DR, Tleyjeh IM, Berbari EF, et al. Incidence of lower- extremity cellulitis: a population-based study in Olmsted county, Minnesota. Mayo Clin Proc 2007; 82:817-21.
7. Fry DE. The economic costs of surgical site infection. Surg Infect (Larchmt) 2002; 3(Suppl 1):S3743.
8. Leaper DJ, van Goor H, Reilly J, et al. Surgical site infection-a European perspective of incidence and economic burden. Int Wound J 2004; 1:247-73.
9. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005; 6:283-95.
10. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in
11. ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008; 168:1585-91.
12. Daum RS. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N Engl J Med 2007; 357: 380-90.
13. Chambers HF. Community-associated MRSA-resistance and virulence converge. N Engl J Med 2005; 352:1485-7.
14. Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society ofAmerica. Clin Infect Dis 2006; 42:657-68.
15. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007; 298: 1763-71.
16. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl JMed2006; 355:666-74.
17. Moellering RC Jr. The growing menace of community-acquired methicillin-resistant Staphylococcus aureus. Ann Intern Med 2006; 144:368-70.
18. Moellering RC Jr. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46:1032-7.
19. Abrahamian FM, Talan DA, Moran GJ. Management of skin and soft- tissue infections in the emergency department. Infect Dis Clin North Am 2008; 22:89-116, vi.
20. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41:1373-406.
21. Vancomycin-resistant Staphylococcus aureus-Pennsylvania, 2002. MMWR Morb Mortal Wkly Rep 2002; 51:902.
22. Guidance for Industry. Antibacterial drug products: use of noninfer- iority studies to support approval. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER), 2007. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm070951.pdf. Accessed 15 June 2009.
23. International Conference on Harmonisation ofTechnical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry. E9, Statistical Principles for Clinical Trials. 1998. Available at: http://www.emea.europa.eu/pdfs/human/ich/036396en.pdf. Accessed 15 June 2009.
24. International Conference on Harmonisation ofTechnical Requirements for Registration of Pharmaceuticals for Human Use. Guidance for Industry. E10, Choice of Control Group and Related Issues in Clinical Trials. 1998. Available at: http://www.fda.gov/downloads/Regulatory Information/Guidances/ ucm129460.pdf. Accessed 15 June 2009.
25. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178-82.
26. Beigelman PM, Rantz LA. The clinical importance of coagulase-positive, penicillin-resistant Staphylococcus aureus. N Engl J Med 1950; 242:353-8.
27. Dowling HF, Lepper MH, Jackson GG. Observations on the epidemiological spread of antibiotic-resistant staphylococci, with measurements of the changes in sensitivity to penicillin and aureomycin. Am J Public Health Nations Health 1953; 43:860-8.
28. Lepper MH, Dowling HF, Jackson GG, Hirsch MM. Epidemiology of penicillin- and aureomycin-resistant staphylococci in a hospital population. AMA Arch Intern Med 1953; 92:40-50.
29. Rountree PM, Barbour RG. Incidence of penicillin-resistant and streptomycin-resistant staphylococci in a hospital. Lancet 1951; 1:435-6.
30. Summers GA. Penicillin-resistant staphylococci; distribution among out patients. Lancet 1952; 1:135-7.
31. Guidance for Industry. Uncomplicated and complicated skin and skin structure infections-developing antimicrobial drugs for treatment. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER), 1998. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm071185 pdf. Accessed 15 June 2009.
32. Dixon WJ, Massey FJ. Introduction to statistical analysis. 4th ed. New York: McGraw Hill, 1983:463.
33. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining trials. In: Egger M, Davey Smith G, Alt- man DG, eds. Systematic reviews in healthcare: meta-analysis in context. London: BMJ Books, 2001.
34. Herrell WE. The clinical use of penicillin: an antibacterial agent of biologic origin. JAMA 1944; 124:622-6.
35. Bedford PD. Penicillin in general practice. Lancet 1946; 1:977.
36. Griffiths E, Jones PF, Shooter RA, Heady JA. The comparative merits of sodium and procaine penicillin given frequently. Br Med J 1949; 2:958-61.
37. King P. Erysipeloid: survey of 115 cases. Lancet 1946; 2:196-8.
38. Logan MA, Metzger WI, Wright LT, Prigot A, Robinson EA. Aureo- mycin in soft tissue infections. Am J Surg 1950; 79:229-43.
39. Howes EL. Topical use of streptomycin in wounds. Am J Med 1947; 2:449-56.
40. Bloom J. Streptomycin therapy in established wound infections. Oral Surg Oral Med Oral Pathol 1949; 3:534.
41. Bush RA. Case of erysipeloid of Rosenbach treated with penicillin. Br Med J 1949; 2:964-5.
42. Barber M, Nellen M, Zoob M. Erysipeloid of Rosenbach: response to penicillin. Lancet 1946; 1:125-7.
43. Hoyne AL, Wolf AA, Prim L. Mortality rates in the treatment of 998 erysipelas patients. JAMA 1939; 113:2279-81.
44. Madsen ST. Scarlet fever and erysipelas in Norway during the last hundred years. Infection 1973; 1:76-81.
45. Panton PN, Adams JE. An investigation into the etiology of erysipelas and allied infections. Lancet 1909; 2:1065-71.
46. Taylor PH, Hughes KEA. Infective dermatoses treated with penicilin. Lancet 1944; 2:780-4.
47. Meleney FL. Penicillin in the treatment of established surgical infections. Ann Surg 1946; 124:962-78.
48. Keefer CS, Blake FG, Marshall Jr. EK, Lockwood JS, Wood BW Jr. Penicillin in the treament of infections. JAMA 1943; 122:1217-24.
49. Herrell WE. Further observations on the clinical use of penicillin. Proceedings of the Staff Meetings of the Mayo Clinic 1943; 18:65-76.
50. Bentley FH. The treatment of flesh wounds by early secondary suture and penicillin. Br J Surg 1944; 32:132-9.
51. Dawson MH, Hobby GL. The clinical use of penicillin: observations in one hundred cases. JAMA 1944; 124:611-21.
52. Lyons C. An investigation of the role of chemotherapy in wound management in the Mediterranean theater. Ann Surg 1946; 123:902-23.
53. Altemeier WA. Penicillin therapy with prolonged interval dosage schedules. Ann Surg 1948; 128:708-13.
54. Southworth J, Dabbs C. Prolonged interval dosing ofaqueous penicillin in surgical infections. South Med J 1949; 42:981-3.
55. Jern HZ, Howes EL, Meleney FL. Studies in bacteriophage. J Lab Clin Med 1934; 19:1257-71.
56. King CO. Radiation therapy of carbuncles. South Med J 1937; 30:903-6.
57. Robinson JA, Hirsh HL, Dowling HF. Oral penicillin in the treatment of various bacterial infections. Am J Med 1948; 4:716-23.
58. Wellman WE, Herrell WE. Procaine penicillin G in sesame oil: a study of reactions and results in 400 cases. Proceedings of the Staff Meetings of the Mayo Clinic 1948; 23:595-600.
59. Davies AM. Penicillin therapy in scarlet fever. Lancet 1948; 1:810.
60. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 2003; 37:1298-303.
61. Spellberg B, Talbot GH, Brass EP, Bradley JS, Boucher HW, Gilbert D. Position paper: recommended design features of future clinical trials of antibacterial agents for community-acquired pneumonia. ClinInfect Dis 2008; 47(Suppl 3):S249-65.
62. Kaul S, Diamond GA, Weintraub WS. Trials and tribulations of noninferiority: the ximelagatran experience. J Am Coll Cardiol 2005; 46:1986-95.
63. Hung HMJ, Wang SJ, Tsong Y, Lawrence J, O'Neil RT. Some fundamental issues with non-inferiority testing in active controlled trials. Stat Med 2003; 22:213-25.
64. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat Med 2003; 22:169-86.
65. Active control non-inferiority studies: theory, assay sensitivity, choice of margin. US Food and Drug Administration, 2002. Available at: http: //www.fda.gov/ohrms/dockets/ac/02/slides/3837s1-02-Temple.ppt. Accessed 5 November 2008.
66. Carroll KJ. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way? Pharm Stat 2006; 5:283-93.
67. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46(Suppl 5):S368-77.
68. Chambers HF, Moellering RC Jr, Kamitsuka P. Clinical decisions: management of skin and soft-tissue infection. N Engl J Med 2008; 359:1063-7.
69. Rajendran PM, Young D, Maurer T, et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob Agents Chemother 2007; 51:4044-8.
70. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349-60.
71. Thomas L. The youngest science. notes of a medicine-watcher. New York: The Viking Press, 1983.
72. Grossman CM. The first use of penicillin in the United States. Ann Intern Med 2008; 149:135-6.
73. Goldner M. Three generations of experience and thought in microbiology and infection. Can J Infect Dis 2003; 14:329-35.
74. Lesch JE. The first miracle drugs: how the sulfa drugs transformed medicine. New York: Oxford University Press, 2007.
75. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006; 333:597-600.
76. Northey EH. The sulfonamides and allied compounds. 1 948 American Chemical Society Monograph Series. Monograph #106. New York: Reinhold Publishing, 1948.
77. Dixon B. Sulfa's true significance. Microbe 2006; 1:500-1.
78. Chain E, Florey HW, Gardner AD, et al. Penicillin as a chemotherapeutic agent. Lancet 1940; 2:226-8.
79. Abraham EP, Chain E, Fletcher CM, et al. Further observations on penicillin. Lancet 1941; 2:177-188.
80. Ellenberg SS, Temple R. Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Ann Intern Med 2000; 133:464-70.